risedronic acid has been researched along with Otosclerosis in 3 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Otosclerosis: Formation of spongy bone in the labyrinth capsule which can progress toward the STAPES (stapedial fixation) or anteriorly toward the COCHLEA leading to conductive, sensorineural, or mixed HEARING LOSS. Several genes are associated with familial otosclerosis with varied clinical signs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Otosclerosis is a disease of abnormal bone remodeling in the otic capsule." | 1.38 | Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis. ( Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M, 2012) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brookler, K | 1 |
| Brookler, KH | 1 |
| Quesnel, AM | 1 |
| Seton, M | 1 |
| Merchant, SN | 1 |
| Halpin, C | 1 |
| McKenna, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study[NCT04152551] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for risedronic acid and Otosclerosis
| Article | Year |
|---|---|
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.
Topics: Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Etidronic Acid; Hearing Loss, Sensorine | 2009 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation A | 2012 |